Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement